Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer.
Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the weekend, while separately announcing that it was returning Immatics’ bispecific T cell engager.
The world’s leading developer of medical video games pairs up with healthcare engagement innovators to help more HCPs access and embrace game-based learning.
Founded in 2013, RPV has worked with clients around the globe to recruit patients and family caregivers for over 10k projects.
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the market for cancer, influenza and more.
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures.